Trecator-SC is a prescription medication used to treat tuberculosis (TB), a serious infectious disease caused by the bacterium Mycobacterium tuberculosis. The active ingredient in Trecator-SC is ethionamide, a synthetic antimicrobial agent belonging to the class of drugs known as thioamides.
Trecator-SC is a second-line antituberculous drug used in the treatment of tuberculosis, particularly in cases where the bacteria have developed resistance to first-line drugs like isoniazid and rifampin.
Ethionamide
, the active ingredient in
Trecator-SC, was first synthesized in 1956 and has been widely used in the treatment of drug-resistant tuberculosis since then. The primary medical use of
Trecator-SC is in the treatment of tuberculosis caused by Mycobacterium tuberculosis, especially in cases of drug-resistant or multi-drug resistant TB.
Ethionamide
works by inhibiting the synthesis of mycolic acids, which are essential components of the cell wall of Mycobacterium tuberculosis.
Trecator-SC (ethionamide) disrupts the synthesis of mycolic acids, which are vital for the structural integrity of the cell wall in Mycobacterium tuberculosis. This disruption leads to the weakening and eventual death of the bacteria, making it an effective antimicrobial agent against tuberculosis.
Trecator-SC is primarily used in combination with other antituberculous drugs to treat drug-resistant forms of tuberculosis, such as multi-drug resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB). It is considered a second-line agent and is typically used when first-line drugs like isoniazid and rifampin are ineffective or contraindicated. While its primary use is in the treatment of tuberculosis,
Trecator-SC has also been explored for potential off-label uses, such as the treatment of certain non-tuberculous mycobacterial
infections. However, these off-label uses are not widely accepted or recommended without further research and clinical evidence.
Trecator-SC is often used in combination with other antituberculous drugs, such as cycloserine, para-aminosalicylic acid (PAS), and fluoroquinolones, to increase the effectiveness of treatment and reduce the risk of drug resistance development.
Combination therapy is recommended for the management of drug-resistant tuberculosis. The typical adult dosage of
Trecator-SC is 500-1000 mg once daily, taken with food to improve absorption and minimize gastrointestinal side effects. The dosage may be adjusted based on individual patient factors, such as body weight, severity of the
infection, and response to treatment. For children, the recommended dosage of
Trecator-SC is 15-20 mg/kg of body weight, once daily, not exceeding 1 gram per day. Pediatric dosages should be carefully calculated based on the child’s weight and monitored closely for potential adverse effects. Dosage adjustments may be necessary in patients with renal impairment or other comorbidities. In some cases,
Trecator-SC dosage may need to be re-titrated based on the patient’s response to treatment, side effects, and other factors. It is recommended to administer
Trecator-SC with pyridoxine (vitamin B6) to help prevent potential neurotoxicity and peripheral neuropathy associated with the drug. If a patient is switching from
Trecator-SC sugar-coated tablets to the regular tablet formulation, the dosage should be adjusted accordingly, as the bioavailability may differ between the two formulations. Some of the most common side effects associated with
Trecator-SC include gastrointestinal disturbances (nausea, vomiting, diarrhea, abdominal pain), loss of appetite, metallic taste in the mouth, and dizziness. These side effects are generally mild and may subside with continued treatment or dose adjustments. In rare cases,
Trecator-SC can cause severe cutaneous reactions, such as
Stevens-Johnson syndrome
(SJS) and toxic epidermal necrolysis (TEN). These reactions can be life-threatening and require immediate medical attention and discontinuation of the drug. If severe or persistent side effects occur, the dosage of
Trecator-SC may need to be adjusted or the drug may need to be discontinued. Close monitoring and management of side effects are crucial, and patients should be instructed to report any adverse reactions promptly. Long-term use of
Trecator-SC may potentially lead to optic neuritis, peripheral neuropathy, hepatotoxicity, and other adverse effects. Regular monitoring and follow-up are recommended for patients on prolonged treatment with
Trecator-SC.
Trecator-SC is contraindicated in patients with known hypersensitivity to ethionamide or any of the inactive ingredients in the formulation. It should also be avoided in patients with severe hepatic impairment or acute liver disease.
Trecator-SC may interact with various medications, including antacids, anticonvulsants, and certain antibiotics. Patients should inform their healthcare provider about all medications they are taking to avoid potential interactions. Caution should be exercised when prescribing
Trecator-SC to pregnant or breastfeeding women, as well as elderly patients and those with renal or hepatic impairment, as dosage adjustments may be necessary.
Alcohol consumption should be avoided while taking
Trecator-SC, as it may increase the risk of hepatotoxicity. Patients should also be cautioned about the potential for increased toxicity when
Trecator-SC is combined with other hepatotoxic drugs or substances.
Trecator-SC may interact with certain other antibiotics, such as isoniazid and rifampin, potentially leading to increased or decreased concentrations of either drug. Close monitoring and dosage adjustments may be necessary when
Trecator-SC is used in combination with other antibiotics.
Trecator-SC may interact with various non-antibiotic drugs, including antacids, anticonvulsants, and certain medications metabolized by the liver enzymes. These interactions can potentially alter the effectiveness or toxicity of either drug, and careful monitoring is recommended.
Trecator-SC may interfere with certain laboratory tests, such as thyroid function tests and glucose monitoring. Patients should inform their healthcare provider about any ongoing laboratory tests to ensure accurate interpretation of results.
Trecator-SC (ethionamide) is well absorbed from the gastrointestinal tract after oral administration. It is widely distributed throughout the body, including the central nervous system.
Ethionamide is primarily metabolized in the liver by enzymatic processes. The metabolites and unchanged drug are excreted through both renal and biliary routes. The peak plasma concentrations of ethionamide are typically reached within 2-4 hours after oral administration. The elimination half-life of
Trecator-SC is approximately 2-3 hours.
Trecator-SC is the brand name for the formulation containing ethionamide. Other brand names for ethionamide include Trecator and Ethion. The availability of
Trecator-SC may vary across different countries and regions. In recent years, there have been reports of discontinuation and shortages of
Trecator-SC in certain markets, leading to the exploration of alternative formulations or sources of ethionamide for the treatment of drug-resistant tuberculosis. Several clinical trials have been conducted to evaluate the efficacy and safety of
Trecator-SC (ethionamide) in the treatment of tuberculosis, particularly drug-resistant forms. These studies have demonstrated its effectiveness when used in combination with other antituberculous drugs.
Trecator-SC has been compared to other second-line antituberculous drugs, such as cycloserine and para-aminosalicylic acid, in various clinical trials. The results have shown comparable or superior efficacy of
Trecator-SC in certain cases, particularly when used as part of a multi-drug regimen. Major health organizations, such as the
World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC), have published guidelines and recommendations for the use of
Trecator-SC in the treatment of drug-resistant tuberculosis. These guidelines provide evidence-based protocols for optimal dosing, combination therapy, and monitoring. Patient information leaflets for
Trecator-SC typically include detailed information on the proper use of the medication, potential side effects, warnings and precautions, and instructions for reporting any adverse reactions or concerns to healthcare providers. Healthcare providers should discuss the importance of adhering to the prescribed treatment regimen, the potential for
drug interactions, and the need for regular monitoring and follow-up with patients taking
Trecator-SC. Patients should be counseled on the importance of taking
Trecator-SC as prescribed and not missing doses, as this can contribute to the development of drug resistance. Regular monitoring for side effects and efficacy through laboratory tests and clinical assessments is also crucial.
Trecator-SC (ethionamide) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of tuberculosis caused by Mycobacterium tuberculosis.
Trecator-SC and other ethionamide formulations have received regulatory approvals in various countries around the world for the treatment of tuberculosis, particularly drug-resistant forms.
Ethionamide has been available for several decades, and its patents have expired in most countries. However, specific formulations or combinations may be protected by intellectual property rights held by pharmaceutical companies or research institutions. For detailed drug information and advanced medical guidance on the use of
Trecator-SC (ethionamide), healthcare professionals should consult scientific resources, medical journals, and expert recommendations from relevant professional organizations and regulatory bodies. Specific topics that may be covered in depth for healthcare professionals include pharmacokinetic and pharmacodynamic data, resistance mechanisms, combination therapy protocols, and specialized patient populations or clinical scenarios.
Ethionamide, the active ingredient in
Trecator-SC, has the chemical formula C
8H
10N
2S and a molecular weight of 166.24 g/mol. It is a synthetic derivative of isonicotinic acid and belongs to the class of thioamides.
Ethionamide can be synthesized through various chemical processes, often involving the reaction of isonicotinic acid and thiosemicarbazide. The manufacturing process involves purification and formulation into tablet or other dosage forms.
Ethionamide is a crystalline solid with a melting point of 161-163°C. It is soluble in organic solvents like ethanol and chloroform but has limited solubility in water.
Ethionamide is a relatively stable compound but may undergo chemical reactions under certain conditions, such as high temperatures or in the presence of strong oxidizing agents.
Trecator-SC: Uses, Side Effects, and Dosage Info
Table of Contents
1. Overview of Trecator-SC
2. Medical Uses of
Trecator-SC
Mechanism of Action
Treatment of
Tuberculosis (TB)
Alternative Uses and Off-Label
Prescriptions
Combination with Other Medications
3. Dosage and Administration
Standard Dosage for Adults
Pediatric Dosage Guidelines
Adjustments and Re-Titration
Administration with
Pyridoxine
Instructions for Switching from
Trecator-SC Sugar-Coated Tablets
4. Side Effects and Adverse Reactions
Common Side Effects
Severe
Cutaneous Reactions
Management and Discontinuation Guidelines for Side Effects
Potential Long-term Effects
5. Warnings and Precautions
Contraindications
Drug Interactions
Special Populations Considerations
Alcohol and Other Drug Usage
6. Drug Interactions
Interaction with Other
Antibiotics
Interaction with Non-
Antibiotic Drugs
Effects on Laboratory Tests
7.
Pharmacokinetics and Pharmacodynamics
Absorption and Distribution
Metabolism and Elimination
Peak
Plasma Concentrations and Half-life
8. Brand Names and Availability
9. Clinical Studies and Efficacy
Synopsis of Major Clinical Trials
Comparative Efficacy with Other Antituberculous Drugs
Clinical Guidelines and Recommendations
10. Patient Information and
Counseling
Detailed Patient Information Leaflet Content
Key Points to Discuss with Patients
Patient
Counseling on Adherence and
Monitoring
11. Regulatory and Legal Aspects
FDA Approval Status
Regulatory Approvals Worldwide
Legal Issues and Intellectual Property
12. Advanced Medical Information
13.
Ethionamide Chemical Profile
Chemical Structure and Formulation
Synthesis and Manufacturing Process
Chemical Properties and Reactivity
14. Historical Context and Development
